8:10 am – 8:20 am Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer in a real-world scenario: the neo-real/ GBECAM-0123 study
Renata Rodrigues da Cunha Colombo Bonadio (BRA)
8:20 am – 8:30 am Just one weekly session of strength or combined training preserves cellular integrity, cardiorespiratory fitness, and increases neuromuscular strength in women with breast cancer during chemotherapy: a randomized controlled trial
Rafael Ribeiro Alves (BRA)
8:30 am – 8:40 am Low-intensity exercises during chemotherapy infusion for fatigue, functionality and neuropathy in women with breast cancer
Brenda Taynara Macedo da Costa (BRA)
8:40 am – 8:50 am Discussion
8:55 am – 9:15 am Mini conference: Incidence of breast cancer in young women and the importance of screening
Luciano Fernandes Chala (BRA)
Chairman
Ruffo de Freitas Junior (BRA)
Speaker
9:15 am – 9:25 am Discussion
Linei Augusta Brolini Dellê Urban (BRA)
Marcelo Antonini (BRA)
9:30 am – 9:50 am Mini conference: De-escalation (and end) of the axilla in all scenarios? (Recorded class)
Augusto Tufi Hassan (BRA)
Chairman
Toralf Reimer (GER)
Speaker
9:50 am – 10:30 am Coffee Break
10:30 am – 11:10 am Diamond Satellite Symposium – MSD:
New horizons for women with high-risk, early-stage TNBC: overal survival with immunotherapy and the multidisplinary treatment -
ONLY PRESCRIBERS
Fabiana Baroni Alves Makdissi (BRA)
Speaker
Luciana Landeiro (BRA)
Speaker
11:10 am 11:40 am Gold Satellite Symposium – LILLY:
Recurrence risk in N1 HR+/HER2-: clinical case discussion
ONLY PRESCRIBERS AND PHARMACISTS
Antonio Carlos Buzaid (BRA)
Speaker
Cristiano Augusto Andrade de Resende (BRA)
Speaker
11:40 pm – 11:45 am BBCS 2025 Awards
Andre Mattar (BRA)
Awarded
Ruffo de Freitas Junior (BRA)
Coordinator
Ricardo Caponero (BRA)
Coordinator
Renata Rodrigues da Cunha Colombo Bonadio (BRA)
Coordinator
11:45 pm – 12:05 pm Mini Conference: Building bridges between clinical reality and scientific production
Ricardo Caponero (BRA)
Chairman
Andre Mattar (BRA)
Speaker
12:05 pm – 1:35 pm
First Novartis and Roche Symposium - Advances and Challenges in the Treatment of Breast Cancer in the SUS
With lunch box
5’ Opening
Ruffo de Freitas Junior (BRA)
10’ The process of incorporating innovations into the Clinical Protocol and Therapeutic Guidelines (PCDT)
Susana Ramalho (BRA)
15’ Updates from the Clinical Protocol and Therapeutic Guidelines (PCDT) to the Diagnostic and Therapeutic Guidelines (DDT)
Renata Rodrigues da Cunha Colombo Bonadio (BRA)
10’ The *SUS I experience is different from yours *SUS = Brazilian Unified Health System
Luciana Holtz de Camargo Barros (BRA)
15’ Discussion
5’ Closing
2 pm – 2:20 pm Satellite Symposium – Oncoclínicas: Locally advanced TNBC with complete response to systemic treatment – when to optimize pembrolizumab as adjuvant
Danielle Laperche dos Santos (BRA)
Speaker
João Nunes de Matos Neto (BRA)
Speaker
2:20 pm – 2:40 pm Mini Conference: Patient-centered treatment decision: challenges to its real implementation in medical practice
Mayza Lemes Duarte Frota (BRA)
Chairwoman
Solange Moraes Sanches (BRA)
Speaker
2:40 pm – 3:10 pm Gold Satellite Symposium – Daiichi Sankyo: New Anti-TROP 2 therapies for luminal breast cancer
ONLY PRESCRIBERS
Cristiano Augusto Andrade de Resende (BRA)
Speaker
3:10 pm – 3:30 pm Silver Satellite Symposium – ROCHE: Evolution in the treatment of breast cancer HR+/HER2- with PI3K mutation: how far have we come and where are we headed? (ONLY PRESCRIBERS)
Gisah Guilgen (BRA)
Speaker
Carlos Henrique dos Anjos (BRA)
Debater
Ruffo de Freitas Junior (BRA)
Debater
General session 2
3:30 pm – 4:10 pm
René Aloisio da Costa Vieira (BRA)
Coordinator
Idam de Oliveira Junior (BRA)
Discussants
Lilian Soares Couto (BRA)
Discussants
3:30 pm – 3:40 pm DENSE-BBREAST Study: dose-dense neoadjuvant chemotherapy in breast cancer: a network meta-analysis of efficacy and toxicity
Andre Mattar (BRA)
3:40 pm – 3:50 pm Innovative platform for chemoresistance: advancing functional precision medicine in breast cancer
Martina Lichtenfels (BRA)
3:50 pm – 4 pm Machine learning-based transcriptomic model enhances prognostic stratification in breast cancer
5 pm – 5:10 pm Omission of axillary surgery in early breast cancer with negative lymph nodes: a systematic review and meta-analysis of randomized clinical trials
Bárbara Bizzo Castelo (BRA)
5:10 pm – 5:20 pm Updated meta-analysis of randomized trials: pCR as a prognostic marker for survival in breast cancer treated with neoadjuvant chemotherapy
Marcelo Antonini (BRA)
5:20 pm – 5:30 pm Metronomic versus standard fixed dosing chemotherapy in HER2-negative metastatic breast cancer: a reconstructed individual patient data meta-analysis
Anelise Poluboiarinov Cappellaro (BRA)
5:30 pm – 5:40 pm Discussion
General session 4
5:40 pm – 6:20 pm
Max Mano (BRA)
Coordinator
Franklin Fernandes Pimentel (BRA)
Discussants
Renata Rodrigues da Cunha Colombo Bonadio (BRA)
Discussants
5:40 pm – 5:50 pm CDK4/6 Inhibitor plus endocrine therapy after progression on CDK4/6 inhibition in HR+/HER2- advanced breast cancer: a systematic review and meta-analysis (REIGNITE Study)
Luís Felipe Leite da Silva (BRA)
5:50 pm – 6 pm GRPR as a prognostic biomarker and mediator of doxorubicin resistance in breast cancer
Martina Lichtenfels (BRA)
6 pm – 6:10 pm Breast surgery for metastatic breast cancer: a update of Cochrane systematic review
